Patent
The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.
1. Isolated Lactobacillus cells, which are capable of aggregating to Helicobacter pylori under culture conditions of the human digestive tract wherein the cells belong to one of the strains DSM 17646, DSM 17647, DSM 17648, DSM 17649, DSM 17650, DSM 17651, DSM 17652 or DSM 17653.
2. A pharmaceutical composition and/or dietetic composition comprising a physiologically effective dose of Lactobacillus cells according to claim 1 and a physiologically tolerated carrier.
3. The pharmaceutical composition of claim 2 , wherein the composition contains 10 2 to 10 15 Lactobacillus cells.
4. The pharmaceutical composition of claim 2 , wherein the composition is prepared for oral administration.
5. The pharmaceutical composition of claim 2 , wherein the Lactobacillus cells are lyophilized.
6. The pharmaceutical composition of claim 2 , wherein the carrier is selected from the group consisting of maltodextrin, microcrystalline cellulose, starch, corn starch, levulose, lactose, dextrose, and mixtures of said carriers.
7. The pharmaceutical composition of claim 2 , wherein the composition contains 0.1 to 95% by weight carrier and 5 to 99.9% by weight lyophilized Lactobacillus cells.
8. The dietetic composition of claim 2 , wherein the composition contains 10 2 to 10 15 Lactobacillus cells.
9. The dietetic composition of claim 2 , wherein the physiologically tolerated carrier is a food material.
10. A method for producing a pharmaceutical and/or dietetic composition of claim 5 , comprising mixing a physiologically effective quantity of the lyophilized Lactobacillus cells with the physiologically tolerated carrier and preparing the composition for oral administration.
11. A method for preventing and/or treating a person who suffers from a disease caused by a Helicobacter pylori infection or is suspected to fall ill with a disease caused by a Helicobacter pylori infection, comprising administering to the person a physiologically effective dose of a pharmaceutical and/or dietetic composition of claim 2 one to five times per day.
12. Isolated Lactobacillus cells of claim 1 which are capable of inhibiting the urease activity of Helicobacter pylori , wherein the pylori bacteria in the aggregates lose the ability to protect against the attack of stomach acid.
13. Isolated Lactobacillus cells according to claim 1 , wherein the culture conditions are culture conditions of the stomach.
14. The pharmaceutical composition of claim 3 , wherein the composition contains 10 6 to 10 12 Lactobacillus cells.
15. The pharmaceutical composition of claim 3 , wherein the composition contains 10 8 to 10 12 Lactobacillus cells.
16. The pharmaceutical compositions of claim 3 , wherein the composition contains 10 8 to 10 10 Lactobacillus cells.
17. The dietetic composition of claim 8 , wherein the composition contains 10 6 to 10 9 Lactobacillus cells.
18. The dietetic composition of claim 8 , wherein the composition contains 10 7 to 10 9 Lactobacillus cells.
19. The dietetic composition of claim 9 , wherein the food material is selected from the group comprising milk products, fermented milk products, milk, yogurt, cheese, cereals, muesli bars, and children food preparations.
20. A method for producing a pharmaceutical and/or dietetic composition of claim 2 , wherein a physiologically effective quantity of the Lactobacillus cells are mixed with the physiologically tolerated carrier and prepared for the oral administration.